Biodesix, Inc.
http://www.biodesix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biodesix, Inc.
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts.
Tivozanib Non-Oncology Buy-Back Gives Quick Cash To AVEO
In a move that will generate further useful cash for AVEO, Kyowa Kirin has reacquired global rights to non-oncology uses of tivozanib.
Breakthrough Status, Big Investments For Liquid Biopsies
The growth potential of liquid biopsy diagnostics is drawing increasing attention, with several recent breakthrough device designations from the US FDA, big funding rounds, and major acquisitions all in play.
Biodesix Buys US Laboratory Assets From Oncimmune
Biodesix is expanding its portfolio of lung cancer diagnostic tests and acquiring the US assets of UK company Oncimmune.
Company Information
- Industry
- Digital Health
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Other Names / Subsidiaries
-
- Indi
- Integrated Diagnostics, Inc.
- Homestead Clinical